Clinical Trial Update: Dose-escalation Study of BIBH 1 in Patients With Non-small Cell Lung Cancer Scheduled for Surgical Resection [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation trial of BIBH 1 in patients with non-small cell lung cancer scheduled for surgical resection; the study status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BIBH 1

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Lung Neoplasms | Phase 1 | Status: TERMINATED